In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, February 04, 2019

**Test Changes** - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

**Discontinued Tests** - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.
<table>
<thead>
<tr>
<th>Test Code</th>
<th>Test Name</th>
<th>Method / CPT Code</th>
<th>Specimen Req.</th>
<th>Stability</th>
<th>Scope</th>
<th>Units</th>
<th>Reference Comments</th>
<th>Discontinue</th>
</tr>
</thead>
<tbody>
<tr>
<td>3124B</td>
<td>1-Naphthol, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3124SP</td>
<td>1-Naphthol, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3124U</td>
<td>1-Naphthol, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5903H</td>
<td>Amphetamines Confirmation (Qualitative), Hair</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0980SP</td>
<td>Carbaryl and Metabolite, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0980U</td>
<td>Carbaryl and Metabolite, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0980B</td>
<td>Carbaryl, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8073B</td>
<td>DUID/DRE Panel, Blood (Forensic) (CSA) - IN State Tox Lab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1569B</td>
<td>Diclofenac, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1569SP</td>
<td>Diclofenac, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1569U</td>
<td>Diclofenac, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2067B</td>
<td>Etodolac, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2067SP</td>
<td>Etodolac, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2067U</td>
<td>Etodolac, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2082SP</td>
<td>Fenoprofen, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2095SP</td>
<td>Flurbiprofen, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2095U</td>
<td>Flurbiprofen, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52090B</td>
<td>Ibuprofen / Naproxen Confirmation, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52090FL</td>
<td>Ibuprofen / Naproxen Confirmation, Fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52090SP</td>
<td>Ibuprofen / Naproxen Confirmation, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52090TI</td>
<td>Ibuprofen / Naproxen Confirmation, Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52090U</td>
<td>Ibuprofen / Naproxen Confirmation, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2390B</td>
<td>Ibuprofen, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2390FL</td>
<td>Ibuprofen, Fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2390SP</td>
<td>Ibuprofen, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2390U</td>
<td>Ibuprofen, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2410B</td>
<td>Indomethacin, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2410SP</td>
<td>Indomethacin, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2410U</td>
<td>Indomethacin, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2486B</td>
<td>Ketoprofen, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2486SP</td>
<td>Ketoprofen, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2482B</td>
<td>Ketorolac, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test Code</td>
<td>Test Name</td>
<td>Test Name</td>
<td>Method / CPT Code</td>
<td>Specimen Req.</td>
<td>Stability</td>
<td>Scope</td>
<td>Units</td>
<td>Reference Comments</td>
</tr>
<tr>
<td>-----------</td>
<td>------------------------------------</td>
<td>-----------</td>
<td>-------------------</td>
<td>---------------</td>
<td>-----------</td>
<td>-------</td>
<td>-------</td>
<td>-------------------</td>
</tr>
<tr>
<td>2482SP</td>
<td>Ketorolac, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2482U</td>
<td>Ketorolac, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52421SP</td>
<td>Memantine Confirmation, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2581SP</td>
<td>Memantine, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3045B</td>
<td>Modafinil / Armodafinil, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3045SP</td>
<td>Modafinil / Armodafinil, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3107B</td>
<td>Nabumetone as Metabolite, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3107SP</td>
<td>Nabumetone as Metabolite, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3107U</td>
<td>Nabumetone as Metabolite, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3122B</td>
<td>Naphthalene and Metabolite, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3122SP</td>
<td>Naphthalene and Metabolite, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52406B</td>
<td>Naproxen Confirmation, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52406SP</td>
<td>Naproxen Confirmation, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52406U</td>
<td>Naproxen Confirmation, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3130B</td>
<td>Naproxen, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3130FL</td>
<td>Naproxen, Fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3130SP</td>
<td>Naproxen, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3130U</td>
<td>Naproxen, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3223B</td>
<td>Nonsteroidal Anti-Inflammatory Drug Panel, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3223SP</td>
<td>Nonsteroidal Anti-Inflammatory Drug Panel, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3223U</td>
<td>Nonsteroidal Anti-Inflammatory Drug Panel, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3286B</td>
<td>Oxaprozin, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3286SP</td>
<td>Oxaprozin, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52103B</td>
<td>Phenylbutazone and Metabolite Confirmation, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52103FL</td>
<td>Phenylbutazone and Metabolite Confirmation, Fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52103SP</td>
<td>Phenylbutazone and Metabolite Confirmation, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52103TI</td>
<td>Phenylbutazone and Metabolite Confirmation, Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52103U</td>
<td>Phenylbutazone and Metabolite Confirmation, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3700B</td>
<td>Phenylbutazone and Metabolite, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3700SP</td>
<td>Phenylbutazone and Metabolite, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test Code</td>
<td>Test Name</td>
<td>Method / CPT Code</td>
<td>Specimen Req.</td>
<td>Stability</td>
<td>Scope</td>
<td>Units</td>
<td>Reference Comments</td>
<td>Discontinue</td>
</tr>
<tr>
<td>-----------</td>
<td>------------------------------------------------</td>
<td>-------------------</td>
<td>---------------</td>
<td>-----------</td>
<td>-------</td>
<td>-------</td>
<td>---------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>3700U</td>
<td>Phenylbutazone and Metabolite, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3781B</td>
<td>Piroxicam, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3781SP</td>
<td>Piroxicam, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3781U</td>
<td>Piroxicam, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4505B</td>
<td>Tolmetin, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4505SP</td>
<td>Tolmetin, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Test Changes

3124SP 1-Naphthol, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.
Units were changed.
Methods/CPT Codes were changed [LC-MS/MS (82542)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial
using approved guidelines.
Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 2 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)

Scope of Analysis: LC-MS/MS (82542): 1-Naphthol

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-Naphthol</td>
<td>ng/mL</td>
<td>Occupational exposure to 640 mcg/cubic meter carbaryl during pesticide application resulted in a peak concentration of 500 ng/mL 1-naphthol in serum. The blood to serum ratio is not known for this compound.</td>
</tr>
</tbody>
</table>

5903H Amphetamines Confirmation (Qualitative), Hair

Summary of Changes: Scope of Analysis was changed.
Order of Reporting was changed.
Methods/CPT Codes were changed [LC-MS/MS (80326, 80359)]
Ephedrine / Pseudoephedrine, MDEA and Phentermine were removed.

Scope of Analysis: LC-MS/MS (80326, 80359): Amphetamine, Methamphetamine, MDA, MDMA

0980SP Carbaryl and Metabolite, Serum/Plasma
Test Changes

Summary of Changes:
- Specimen Requirements were changed.
- Specimen Requirements (Transport Temperature) were changed.
- Specimen Requirements (Specimen Container) were changed.
- Specimen Requirements (Special Handling) were changed.
- Specimen Requirements (Rejection Criteria) were changed.
- Stability was changed.
- Reference Comment was changed.
- Units were changed.
- Methods/CPT Codes were changed [LC-MS/MS (82542)]

Specimen Requirements:
- 1 mL Serum or Plasma

Transport Temperature:
- Refrigerated

Specimen Container:
- Plastic container (preservative-free)

Light Protection:
- Not Required

Special Handling:
- Serum: Collect sample in Red top tube
- Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
- Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.

Rejection Criteria:
- Received Room Temperature. Polymer gel separation tube (SST or PST).

Stability:
- Room Temperature: 1 day(s)
- Refrigerated: 15 day(s)
- Frozen (-20 °C): 15 day(s)

Scope of Analysis:
- LC-MS/MS (82542): Carbaryl, 1-Naphthol

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbaryl</td>
<td>ng/mL</td>
<td>Carbaryl is a carbamate insecticide that may produce cholinergic toxicity following ingestion. Fatal concentrations in blood range from 6000 to 27000 ng/mL. Occupational exposure to 640 mcg/cubic meter during pesticide application resulted in a peak serum concentration of 0.1 ng/mL. The blood to serum ratio is not known for this compound.</td>
</tr>
<tr>
<td>1-Naphthol</td>
<td>ng/mL</td>
<td>Occupational exposure to 640 mcg/cubic meter carbaryl during pesticide application resulted in a peak concentration of 500 ng/mL 1-naphthol in serum. The blood to serum ratio is not known for this compound.</td>
</tr>
</tbody>
</table>

0980B  Carbaryl, Blood
Test Changes

Summary of Changes:  Test Name was changed.
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Scope of Analysis was changed.
Reference Comment was changed.
Units were changed.
Methods/CPT Codes were changed [LC-MS/MS (82542)]
1-Naphthol was removed.

Specimen Requirements:  1 mL Blood
Transport Temperature:  Frozen
Specimen Container:  Lavender top tube (EDTA)
  Light Protection:  Not Required
  Special Handling:  None
  Rejection Criteria:  Received Room Temperature.  Received Refrigerated.
Stability:  Room Temperature: Not Stable  Refrigerated: 1 day(s)
  Frozen (-20 °C): 15 day(s)
Scope of Analysis:  LC-MS/MS (82542): Carbaryl

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbaryl</td>
<td>ng/mL</td>
<td>Carbaryl is a carbamate insecticide that may produce cholinergic toxicity following ingestion. Fatal concentrations in blood range from 6000 to 27000 ng/mL. Occupational exposure to 640 mcg/cubic meter during pesticide application resulted in a peak serum concentration of 0.1 ng/mL. The blood to plasma ratio is not known for this compound.</td>
</tr>
</tbody>
</table>

8073B  DUID/DRE Panel, Blood (Forensic) (CSA) - IN State Tox Lab

Summary of Changes:  Specimen Requirements were changed.

Specimen Requirements:  6 mL Blood
Transport Temperature:  Refrigerated
Specimen Container:  Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
  Light Protection:  Not Required
  Special Handling:  None
  Rejection Criteria:  Received Room Temperature.

1569B  Diclofenac, Blood
Test Changes

Summary of Changes: Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Diclofenac

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diclofenac</td>
<td>mcg/mL</td>
<td>During chronic therapy with 150 mg Diclofenac (daily) for treatment of arthritis, peak plasma concentrations ranged from 0.1 - 2.2 mcg/mL with a mean concentration of 0.8 mcg/mL. The blood to plasma ratio is approximately 0.7.</td>
</tr>
</tbody>
</table>

1569SP Diclofenac, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Test Changes

Scope of Analysis: LC-MS/MS (80329): Diclofenac
Method (CPT Code) LC-MS/MS (80329): Diclofenac

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diclofenac</td>
<td>mcg/mL</td>
<td>During chronic therapy with 150 mg Diclofenac (daily) for treatment of arthritis, peak plasma concentrations ranged from 0.1 - 2.2 mcg/mL with a mean concentration of 0.8 mcg/mL.</td>
</tr>
</tbody>
</table>

2067B  Etodolac, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 15 day(s) Refrigerated: 15 day(s) Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Etodolac

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etodolac</td>
<td>mcg/mL</td>
<td>Mean peak plasma concentration after a single 600 mg oral dose 37 +/- 9 mcg/mL at 80 minutes post dose. The blood to plasma ratio is approximately 0.6.</td>
</tr>
</tbody>
</table>

2067SP  Etodolac, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]
Test Changes

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Etodolac

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etodolac</td>
<td>mcg/mL</td>
<td>Mean peak plasma concentration after a single 600 mg oral dose 37 +/- 9 mcg/mL at 80 minutes post dose.</td>
</tr>
</tbody>
</table>

**Fenoprofen, Serum/Plasma**

Summary of Changes: Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Fenoprofen
## Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fenoprofen</td>
<td>mcg/mL</td>
<td>Mean peak plasma concentration after a single 600 mg oral dose: 50 mcg/mL at 2 hours post dose.</td>
</tr>
</tbody>
</table>

### 2095SP  Flurbiprofen, Serum/Plasma

**Summary of Changes:**
- Specimen Requirements (Specimen Container) were changed.
- Specimen Requirements (Special Handling) were changed.
- Stability was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80329)]

<table>
<thead>
<tr>
<th>Specimen Requirements:</th>
<th>1 mL Serum or Plasma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transport Temperature:</td>
<td>Refrigerated</td>
</tr>
<tr>
<td>Specimen Container:</td>
<td>Plastic container (preservative-free)</td>
</tr>
<tr>
<td>Light Protection:</td>
<td>Not Required</td>
</tr>
</tbody>
</table>
| Special Handling:      | Serum: Collect sample in Red top tube  
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.  
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. |
| Rejection Criteria:    | Polymer gel separation tube (SST or PST). |
| Stability:             | Room Temperature: 15 day(s)  
Refrigerated: 15 day(s)  
Frozen (-20 °C): 15 day(s) |
| Scope of Analysis:     | LC-MS/MS (80329): Flurbiprofen |

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flurbiprofen</td>
<td>mcg/mL</td>
<td>Mean peak plasma concentration normalized to a 100 mg oral dose: 16 +/- 5 mcg/mL in geriatric patients at approximately 2.2 hours.</td>
</tr>
</tbody>
</table>

### 52090B  Ibuprofen / Naproxen Confirmation, Blood

**Summary of Changes:**
- Specimen Requirements were changed.
- Stability was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80329), LC-MS/MS (80329)]
Test Changes

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Naproxen
Method (CPT Code) LC-MS/MS (80329): Ibuprofen

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibuprofen</td>
<td>mcg/mL</td>
<td>Following a single 400 mg oral dose, the average peak plasma concentration was 28 mcg/mL (range, 17 to 36 mcg/mL) at approximately 1 hour post dose. Severe symptoms such as hypotension and renal failure are possible above 100 mcg/mL and probable above 200 mcg/mL plasma at approximately 1 hour post dose. The blood to plasma ratio is approximately 0.6. This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen.</td>
</tr>
<tr>
<td>Naproxen</td>
<td>mcg/mL</td>
<td>Average peak and trough levels in individuals receiving 250 mg twice daily for 7 days are reported as 46 mcg/mL and 31 mcg/mL, respectively. The blood to plasma ratio is unknown for this compound.</td>
</tr>
</tbody>
</table>

52090FL  Ibuprofen / Naproxen Confirmation, Fluid

Summary of Changes: Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329), LC-MS/MS (80329)]

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibuprofen</td>
<td>mcg/mL</td>
<td>This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen.</td>
</tr>
</tbody>
</table>

52090SP  Ibuprofen / Naproxen Confirmation, Serum/Plasma
Test Changes

Summary of Changes: Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329), LC-MS/MS (80329)]

Stability:
- Room Temperature: 15 day(s)
- Refrigerated: 15 day(s)
- Frozen (-20 °C): 15 day(s)

Scope of Analysis:
- LC-MS/MS (80329): Naproxen
- LC-MS/MS (80329): Ibuprofen

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibuprofen</td>
<td>mcg/mL</td>
<td>Following a single 400 mg oral dose, the average peak plasma concentration was 28 mcg/mL (range, 17 to 36 mcg/mL) at approximately 1 hour post dose. Severe symptoms such as hypotension and renal failure are possible above 100 mcg/mL and probable above 200 mcg/mL plasma at approximately 1 hour post dose. This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen.</td>
</tr>
<tr>
<td>Naproxen</td>
<td>mcg/mL</td>
<td>Average peak and trough levels in individuals receiving 250 mg twice daily for 7 days are reported as 46 mcg/mL and 31 mcg/mL, respectively.</td>
</tr>
</tbody>
</table>

52090TI  Ibuprofen / Naproxen Confirmation, Tissue

Summary of Changes: Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329), LC-MS/MS (80329)]

Scope of Analysis:
- LC-MS/MS (80329): Naproxen
- LC-MS/MS (80329): Ibuprofen

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibuprofen</td>
<td>mcg/g</td>
<td>This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen.</td>
</tr>
</tbody>
</table>

52090U  Ibuprofen / Naproxen Confirmation, Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329), LC-MS/MS (80329)]
Test Changes

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)

Scope of Analysis: LC-MS/MS (80329): Naproxen
Method (CPT Code) LC-MS/MS (80329): Ibuprofen

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibuprofen</td>
<td>mcg/mL</td>
<td>This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen.</td>
</tr>
</tbody>
</table>

2390B  Ibuprofen, Blood

Summary of Changes: Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

| Stability | Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s) |
| Scope of Analysis | LC-MS/MS (80329): Ibuprofen |

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibuprofen</td>
<td>mcg/mL</td>
<td>Following a single 400 mg oral dose, the average peak plasma concentration was 28 mcg/mL (range, 17 to 36 mcg/mL) at approximately 1 hour post dose. Severe symptoms such as hypotension and renal failure are possible above 100 mcg/mL and probable above 200 mcg/mL plasma at approximately 1 hour post dose. The blood to plasma ratio is approximately 0.6. This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen.</td>
</tr>
</tbody>
</table>

2390FL  Ibuprofen, Fluid

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]
Test Changes

Specimen Requirements: 2 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: Undetermined
Refrigerated: Undetermined
Frozen (-20 °C): Undetermined
Scope of Analysis: LC-MS/MS (80329): Ibuprofen

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibuprofen</td>
<td>mcg/mL</td>
<td>This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen.</td>
</tr>
</tbody>
</table>

2390SP Ibuprofen, Serum/Plasma

Summary of Changes: Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Ibuprofen
Method (CPT Code)
### Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibuprofen</td>
<td>mcg/mL</td>
<td>Following a single 400 mg oral dose, the average peak plasma concentration was 28 mcg/mL (range, 17 to 36 mcg/mL) at approximately 1 hour post dose. Severe symptoms such as hypotension and renal failure are possible above 100 mcg/mL and probable above 200 mcg/mL plasma at approximately 1 hour post dose. This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen.</td>
</tr>
</tbody>
</table>

#### 2390U  Ibuprofen, Urine

**Summary of Changes:** Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]

- **Specimen Requirements:** 1 mL Urine
  - Transport Temperature: Refrigerated
  - Specimen Container: Plastic container (preservative-free)
  - Light Protection: Not Required
  - Special Handling: None
  - Rejection Criteria: None
  - Stability: Room Temperature: 15 day(s), Refrigerated: 15 day(s), Frozen (-20 °C): 15 day(s)

- **Scope of Analysis:** Method (CPT Code) LC-MS/MS (80329): Ibuprofen

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibuprofen</td>
<td>mcg/mL</td>
<td>This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen.</td>
</tr>
</tbody>
</table>

#### 2410B  Indomethacin, Blood

**Summary of Changes:** Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]
Test Changes

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Indomethacin
Method (CPT Code)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indomethacin</td>
<td>mcg/mL</td>
<td>Mean peak plasma concentrations at approximately 2 hours are 1 and 2 mcg/mL following single oral doses of 25 and 50 mg, respectively. The blood to plasma ratio is approximately 0.5.</td>
</tr>
</tbody>
</table>

2410SP   Indomethacin, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 7 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Indomethacin
Method (CPT Code)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indomethacin</td>
<td>mcg/mL</td>
<td>Mean peak plasma concentrations at approximately 2 hours are 1 and 2 mcg/mL following single oral doses of 25 and 50 mg, respectively.</td>
</tr>
</tbody>
</table>
Test Changes

2410U  Indomethacin, Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 15 day(s) Refrigerated: 15 day(s) Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Indomethacin
Method (CPT Code) LC-MS/MS (80329)

2486B  Ketoprofen, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 15 day(s) Refrigerated: 15 day(s) Frozen (-20 °C): 7 day(s)
Scope of Analysis: LC-MS/MS (80329): Ketoprofen
Method (CPT Code) LC-MS/MS (80329)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketoprofen</td>
<td>mcg/mL</td>
<td>Steady state peak plasma concentrations following 200 mg daily oral dosing averaged 2.4 +/- 1.0 mcg/mL for normal release and 3.4 +/- 1.3 mcg/mL for extended release ketoprofen. The blood to plasma ratio is not known for this compound.</td>
</tr>
</tbody>
</table>
Test Changes

2486SP Ketoprofen, Serum/Plasma

Summary of Changes:
- Specimen Requirements (Specimen Container) were changed.
- Specimen Requirements (Special Handling) were changed.
- Stability was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability:
- Room Temperature: 15 day(s)
- Refrigerated: 15 day(s)
- Frozen (-20 °C): 15 day(s)
Scope of Analysis: Method (CPT Code)
- LC-MS/MS (80329): Ketoprofen

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketoprofen</td>
<td>mcg/mL</td>
<td>Steady state peak plasma concentrations following 200 mg daily oral dosing averaged 2.4 +/- 1.0 mcg/mL for normal release and 3.4 +/- 1.3 mcg/mL for extended release ketoprofen.</td>
</tr>
</tbody>
</table>

2482B Ketorolac, Blood

Summary of Changes:
- Specimen Requirements (Specimen Container) were changed.
- Specimen Requirements (Light Protection) were changed.
- Specimen Requirements (Rejection Criteria) were changed.
- Stability was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Test Changes

Stability:
- Room Temperature: 15 day(s)
- Refrigerated: 15 day(s)
- Frozen (-20 °C): 15 day(s)

Scope of Analysis:
- LC-MS/MS (80329): Ketorolac

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketorolac</td>
<td>mcg/mL</td>
<td>Mean peak plasma concentration following: daily oral dosing with 40 mg: 0.9 +/- 0.2 mcg/mL single IV 15 mg dose: 2.5 mcg/mL (within 3 min; adults) single IV 30 mg dose: 4.7 mcg/mL (within 3 min; adults) The ratio of whole blood concentration to serum or plasma concentration is approximately 0.5. This test is not chiral specific and cannot distinguish between the R and S enantiomers of ketorolac.</td>
</tr>
</tbody>
</table>

2482SP Ketorolac, Serum/Plasma

Summary of Changes:
- Specimen Requirements (Specimen Container) were changed.
- Specimen Requirements (Light Protection) were changed.
- Specimen Requirements (Special Handling) were changed.
- Stability was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements:
- 1 mL Serum or Plasma

Transport Temperature:
- Refrigerated

Specimen Container:
- Plastic container (preservative-free)

Light Protection:
- Not Required

Special Handling:
- Serum: Collect sample in Red top tube
- Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.

Rejection Criteria:
- Polymer gel separation tube (SST or PST).

Stability:
- Room Temperature: 15 day(s)
- Refrigerated: 15 day(s)
- Frozen (-20 °C): 15 day(s)

Scope of Analysis:
- LC-MS/MS (80329): Ketorolac

Method (CPT Code)
# Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
</table>
| Ketorolac     | mcg/mL| Mean peak plasma concentration following:  
daily oral dosing with 40 mg: 0.9 +/- 0.2 mcg/mL  
single IV 15 mg dose: 2.5 mcg/mL (within 3 min; adults)  
single IV 30 mg dose: 4.7 mcg/mL (within 3 min; adults)  
This test is not chiral specific and cannot distinguish  
between the R and S enantiomers of ketorolac. |

---

### 52421SP Memantine Confirmation, Serum/Plasma

<table>
<thead>
<tr>
<th>Summary of Changes:</th>
<th>Stability was changed.</th>
</tr>
</thead>
</table>
| Stability:          | Room Temperature: 30 day(s)  
Refrigerated: 30 day(s)  
Frozen (-20 °C): 12 month(s) |

### 2581SP Memantine, Serum/Plasma

<table>
<thead>
<tr>
<th>Summary of Changes:</th>
<th>Stability was changed.</th>
</tr>
</thead>
</table>
| Stability:          | Room Temperature: 30 day(s)  
Refrigerated: 30 day(s)  
Frozen (-20 °C): 12 month(s) |

### 3045B Modafinil / Armodafinil, Blood

| Summary of Changes: | Specimen Requirements were changed.  
Stability was changed.  
Reference Comment was changed.  
Methods/CPT Codes were changed [LC-MS/MS (80342)] |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Specimen Requirements:</td>
<td>1 mL Blood</td>
</tr>
<tr>
<td>Transport Temperature:</td>
<td>Refrigerated</td>
</tr>
<tr>
<td>Specimen Container:</td>
<td>Lavender top tube (EDTA)</td>
</tr>
<tr>
<td>Light Protection:</td>
<td>Not Required</td>
</tr>
<tr>
<td>Special Handling:</td>
<td>None</td>
</tr>
<tr>
<td>Rejection Criteria:</td>
<td>None</td>
</tr>
</tbody>
</table>
| Stability: | Room Temperature: 15 day(s)  
Refrigerated: 15 day(s)  
Frozen (-20 °C): 15 day(s) |
| Scope of Analysis: | LC-MS/MS (80342): Modafinil / Armodafinil |
| Method (CPT Code) | |
**Test Changes**

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modafinil / Armodafinil</td>
<td>mcg/mL</td>
<td>After 7 daily oral doses of 200 or 600 mg Modafinil: Respective mean peak plasma concentrations 6.4 (+/- 0.7) and 17 (+/- 2.0) mcg/mL. Respective mean trough plasma concentrations 1.7 (+/- 0.5) and 4.8 (+/- 0.6) mcg/mL. The blood to plasma ratio is not known for this compound. This test is not chiral specific; therefore, Armodafinil and/or Modafinil may be present.</td>
</tr>
</tbody>
</table>

**3045SP  Modafinil / Armodafinil, Serum/Plasma**

Summary of Changes: Specimen Requirements were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80342)].

<table>
<thead>
<tr>
<th>Specimen Requirements:</th>
<th>1 mL Serum or Plasma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transport Temperature:</td>
<td>Refrigerated</td>
</tr>
<tr>
<td>Specimen Container:</td>
<td>Plastic container (preservative-free)</td>
</tr>
<tr>
<td>Light Protection:</td>
<td>Not Required</td>
</tr>
<tr>
<td>Special Handling:</td>
<td>Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.</td>
</tr>
<tr>
<td>Rejection Criteria:</td>
<td>Polymer gel separation tube (SST or PST).</td>
</tr>
<tr>
<td>Stability:</td>
<td>Room Temperature: 15 day(s) Refrigerated: 15 day(s) Frozen (-20 °C): 15 day(s)</td>
</tr>
<tr>
<td>Scope of Analysis:</td>
<td>LC-MS/MS (80342): Modafinil / Armodafinil</td>
</tr>
<tr>
<td>Method (CPT Code):</td>
<td>Modafinil / Armodafinil</td>
</tr>
</tbody>
</table>

**3107B  Nabumetone as Metabolite, Blood**

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modafinil / Armodafinil</td>
<td>mcg/mL</td>
<td>After 7 daily oral doses of 200 or 600 mg Modafinil: Respective mean peak plasma concentrations 6.4 (+/- 0.7) and 17 (+/- 2.0) mcg/mL. Respective mean trough plasma concentrations 1.7 (+/- 0.5) and 4.8 (+/- 0.6) mcg/mL. This test is not chiral specific; therefore, Armodafinil and/or Modafinil may be present.</td>
</tr>
</tbody>
</table>
Test Changes

Summary of Changes:
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements:
Transport Temperature: Refrigerated
Specimen Container:
   - Lavender top tube (EDTA)
   - Plastic container (preservative-free)
Light Protection: Not Required
Special Handling:
   - Serum: Collect sample in Red top tube
   - Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Rejection Criteria: None

Stability:
   - Room Temperature: 15 day(s)
   - Refrigerated: 15 day(s)
   - Frozen (-20 °C): 15 day(s)

Scope of Analysis:
Method (CPT Code):
   - LC-MS/MS (80329): 6-MNA

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-MNA</td>
<td>mcg/mL</td>
<td>6-MNA (6-Methoxy-2-Naphthylacetic Acid) is the active metabolite of Nabumetone. Steady-state peak plasma concentrations of 6-MNA following a daily oral regimen of 1000 mg Nabumetone: 32-72 mcg/mL at 5 hours in healthy volunteers 15-100 mcg/mL at 6 hours in elderly patients The blood to plasma ratio is not known for this compound.</td>
</tr>
</tbody>
</table>

3107SP  Nabumetone as Metabolite, Serum/Plasma

Summary of Changes:
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements:
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling:
   - Serum: Collect sample in Red top tube
   - Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-MNA</td>
<td>mcg/mL</td>
<td>6-MNA (6-Methoxy-2-Naphthylacetic Acid) is the active metabolite of Nabumetone. Steady-state peak plasma concentrations of 6-MNA following a daily oral regimen of 1000 mg Nabumetone: 32-72 mcg/mL at 5 hours in healthy volunteers; 15-100 mcg/mL at 6 hours in elderly patients</td>
</tr>
</tbody>
</table>

3107U Nabumetone as Metabolite, Urine

Summary of Changes:
- Stability was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80329)]

3122SP Naphthalene and Metabolite, Serum/Plasma

Summary of Changes:
- Specimen Requirements were changed.
- Specimen Requirements (Specimen Container) were changed.
- Specimen Requirements (Special Handling) were changed.
- Reference Comment was changed.
- Units were changed.
- Methods/CPT Codes were changed [LC-MS/MS (84600)]
Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-Naphthol</td>
<td>ng/mL</td>
<td>Occupational exposure to 640 mcg/cubic meter carbaryl during pesticide application resulted in a peak concentration of 500 ng/mL 1-naphthol in serum. The blood to serum ratio is not known for this compound.</td>
</tr>
</tbody>
</table>

52406B Naproxen Confirmation, Blood

Summary of Changes:
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80330)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability:
- Room Temperature: 15 day(s)
- Refrigerated: 15 day(s)
- Frozen (-20 °C): 15 day(s)
Scope of Analysis:

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naproxen</td>
<td>mcg/mL</td>
<td>Average peak and trough levels in individuals receiving 250 mg twice daily for 7 days are reported as 46 mcg/mL and 31 mcg/mL, respectively. The blood to plasma ratio is unknown for this compound.</td>
</tr>
</tbody>
</table>

52406SP Naproxen Confirmation, Serum/Plasma

Summary of Changes:
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80330)]

Stability:
- Room Temperature: 15 day(s)
- Refrigerated: 15 day(s)
- Frozen (-20 °C): 15 day(s)
Scope of Analysis:
Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naproxen</td>
<td>mcg/mL</td>
<td>Average peak and trough levels in individuals receiving 250 mg twice daily for 7 days are reported as 46 mcg/mL and 31 mcg/mL, respectively.</td>
</tr>
</tbody>
</table>

52406U Naproxen Confirmation, Urine

Summary of Changes:
- Specimen Requirements (Specimen Container) were changed.
- Stability was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80330)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80330): Naproxen

3130B Naproxen, Blood

Summary of Changes:
- Specimen Requirements (Specimen Container) were changed.
- Stability was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Naproxen
## Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naproxen</td>
<td>mcg/mL</td>
<td>Average peak and trough levels in individuals receiving 250 mg twice daily for 7 days are reported as 46 mcg/mL and 31 mcg/mL, respectively. The blood to plasma ratio is unknown for this compound.</td>
</tr>
</tbody>
</table>

### 3130FL Naproxen, Fluid

Summary of Changes: Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]

<table>
<thead>
<tr>
<th>Stability</th>
<th>Scope of Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room Temperature: Undetermined</td>
<td>LC-MS/MS (80329): Naproxen</td>
</tr>
<tr>
<td>Refrigerated: Undetermined</td>
<td></td>
</tr>
<tr>
<td>Frozen (-20 °C): Undetermined</td>
<td></td>
</tr>
</tbody>
</table>

### 3130SP Naproxen, Serum/Plasma

Summary of Changes: Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]

<table>
<thead>
<tr>
<th>Stability</th>
<th>Scope of Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room Temperature: 15 day(s)</td>
<td>LC-MS/MS (80329): Naproxen</td>
</tr>
<tr>
<td>Refrigerated: 15 day(s)</td>
<td></td>
</tr>
<tr>
<td>Frozen (-20 °C): 15 day(s)</td>
<td></td>
</tr>
</tbody>
</table>

### 3130U Naproxen, Urine

Summary of Changes: Specimen Requirements (Specimen Container) were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]

<table>
<thead>
<tr>
<th>Specimen Requirements: 1 mL Urine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transport Temperature: Refrigerated</td>
</tr>
<tr>
<td>Specimen Container: Plastic container (preservative-free)</td>
</tr>
<tr>
<td>Light Protection: Not Required</td>
</tr>
<tr>
<td>Special Handling: None</td>
</tr>
<tr>
<td>Rejection Criteria: None</td>
</tr>
</tbody>
</table>
Test Changes

Stability:
- Room Temperature: 15 day(s)
- Refrigerated: 15 day(s)
- Frozen (-20 °C): 15 day(s)

Scope of Analysis: LC-MS/MS (80329): Naproxen

Methods/CPT Codes were changed [LC-MS/MS (80331), LC-MS/MS (80331)]

Nonsteroidal Anti-Inflammatory Drug Panel, Serum/Plasma

Summary of Changes:
- Specimen Requirements (Light Protection) were changed.
- Specimen Requirements (Rejection Criteria) were changed.
- Stability was changed.
- Scope of Analysis was changed.
- Order of Reporting was changed.
- Reference Comment was changed.

Specimen Requirements:
- 1 mL Serum or Plasma

Transport Temperature:
- Refrigerated

Specimen Container:
- Plastic container (preservative-free)

Light Protection:
- Not Required

Special Handling:
- Serum: Collect sample in Red top tube
- Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
- Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.

Rejection Criteria:
- Polymer gel separation tube (SST or PST).

Stability:
- Room Temperature: 7 day(s)
- Refrigerated: 15 day(s)
- Frozen (-20 °C): 15 day(s)

Scope of Analysis:
- LC-MS/MS (80331): Ketorolac, Piroxicam, 6-MNA, Flurbiprofen, Indomethacin, Diclofenac, Ibuprofen
- LC-MS/MS (80331): Tolmetin, Ketoprofen, Naproxen, Oxaprozin, Fenoprofen, Etodolac

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketorolac</td>
<td>mcg/mL</td>
<td>Mean peak plasma concentration following: daily oral dosing with 40 mg: 0.9 +/- 0.2 mcg/mL single IV 15 mg dose: 2.5 mcg/mL (within 3 min; adults) single IV 30 mg dose: 4.7 mcg/mL (within 3 min; adults) This test is not chiral specific and cannot distinguish between the R and S enantiomers of ketorolac.</td>
</tr>
<tr>
<td>Tolmetin</td>
<td>mcg/mL</td>
<td>Reported steady-state plasma concentrations following a 400 mg dose four times a day averaged 45 mcg/mL (range, 8 - 79 mcg/mL).</td>
</tr>
</tbody>
</table>
## Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketoprofen</td>
<td>mcg/mL</td>
<td>Steady state peak plasma concentrations following 200 mg daily oral dosing averaged 2.4 +/- 1.0 mcg/mL for normal release and 3.4 +/- 1.3 mcg/mL for extended release ketoprofen.</td>
</tr>
<tr>
<td>Piroxicam</td>
<td>mcg/mL</td>
<td>The usual plasma concentration during chronic 20 mg daily oral doses is 3 - 8 mcg/mL.</td>
</tr>
<tr>
<td>6-MNA</td>
<td>mcg/mL</td>
<td>6-MNA (6-Methoxy-2-Naphthylacetic Acid) is the active metabolite of Nabumetone. Steady-state peak plasma concentrations of 6-MNA following a daily oral regimen of 1000 mg Nabumetone: 32-72 mcg/mL at 5 hours in healthy volunteers 15-100 mcg/mL at 6 hours in elderly patients</td>
</tr>
<tr>
<td>Naproxen</td>
<td>mcg/mL</td>
<td>Average peak and trough levels in individuals receiving 250 mg twice daily for 7 days are reported as 46 mcg/mL and 31 mcg/mL, respectively.</td>
</tr>
<tr>
<td>Flurbiprofen</td>
<td>mcg/mL</td>
<td>Mean peak plasma concentration normalized to a 100 mg oral dose: 16 +/- 5 mcg/mL in geriatric patients at approximately 2.2 hours.</td>
</tr>
<tr>
<td>Oxpaprin</td>
<td>mcg/mL</td>
<td>Single oral doses of 1200 mg oxaproxin resulted in peak plasma concentrations of 70 mcg/mL at 5 hours in men and 81 mcg/mL at 10 hours in women.</td>
</tr>
<tr>
<td>Fenoprofen</td>
<td>mcg/mL</td>
<td>Mean peak plasma concentration after a single 600 mg oral dose: 50 mcg/mL at 2 hours post dose.</td>
</tr>
<tr>
<td>Indomethacin</td>
<td>mcg/mL</td>
<td>Mean peak plasma concentrations at approximately 2 hours are 1 and 2 mcg/mL following single oral doses of 25 and 50 mg, respectively.</td>
</tr>
<tr>
<td>Diclofenac</td>
<td>mcg/mL</td>
<td>During chronic therapy with 150 mg Diclofenac (daily) for treatment of arthritis, peak plasma concentrations ranged from 0.1 - 2.2 mcg/mL with a mean concentration of 0.8 mcg/mL.</td>
</tr>
<tr>
<td>Etodolac</td>
<td>mcg/mL</td>
<td>Mean peak plasma concentration after a single 600 mg oral dose 37 +/- 9 mcg/mL at 80 minutes post dose.</td>
</tr>
</tbody>
</table>
Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibuprofen</td>
<td>mcg/mL</td>
<td>Following a single 400 mg oral dose, the average peak plasma concentration was 28 mcg/mL (range, 17 to 36 mcg/mL) at approximately 1 hour post dose. Severe symptoms such as hypotension and renal failure are possible above 100 mcg/mL and probable above 200 mcg/mL plasma at approximately 1 hour post dose. This test is not chiral specific and cannot distinguish between the R and S enantiomers of ibuprofen.</td>
</tr>
</tbody>
</table>

3286B Oxaprozin, Blood

Summary of Changes:
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements:
- Transport Temperature: Refrigerated
- Specimen Container: Lavender top tube (EDTA)
- Light Protection: Not Required
- Special Handling: None
- Rejection Criteria: None

Stability:
- Room Temperature: 15 day(s)
- Refrigerated: 15 day(s)
- Frozen (-20 °C): 15 day(s)

Scope of Analysis:
Method (CPT Code): LC-MS/MS (80329): Oxaprozin

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxaprozin</td>
<td>mcg/mL</td>
<td>Single oral doses of 1200 mg oxaprozin resulted in peak plasma concentrations of 70 mcg/mL at 5 hours in men and 81 mcg/mL at 10 hours in women. The blood to plasma ratio is approximately 0.5.</td>
</tr>
</tbody>
</table>

3286SP Oxaprozin, Serum/Plasma

Summary of Changes:
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]
Test Changes

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 15 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Oxaprozin

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxaprozin</td>
<td>mcg/mL</td>
<td>Single oral doses of 1200 mg oxaprozin resulted in peak plasma concentrations of 70 mcg/mL at 5 hours in men and 81 mcg/mL at 10 hours in women.</td>
</tr>
</tbody>
</table>

52103B Phenylbutazone and Metabolite Confirmation, Blood

Summary of Changes: Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Scope of Analysis was changed. Order of Reporting was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 2 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone
Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxyphenbutazone</td>
<td>mcg/mL</td>
<td>Plasma concentrations following 400 mg daily administration of oxyphenbutazone: 27 - 95 mcg/mL. The blood to plasma ratio is unknown for this compound.</td>
</tr>
<tr>
<td>Phenylbutazone</td>
<td>mcg/mL</td>
<td>Steady-state plasma concentrations for patients administered 800 mg daily oral phenylbutazone averaged 100 mcg/mL and ranged from 60 to 150 mcg/mL. The blood to plasma ratio is approximately 0.5. Deaths due to blood dyscrasias have been reported following therapeutic administration.</td>
</tr>
</tbody>
</table>

52103FL  Phenylbutazone and Metabolite Confirmation, Fluid

Summary of Changes: Specimen Requirements were changed. Scope of Analysis was changed. Order of Reporting was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 2 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone

52103SP  Phenylbutazone and Metabolite Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements (Special Handling) were changed. Stability was changed. Scope of Analysis was changed. Order of Reporting was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80329)]
Test Changes

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 2 day(s)
Refrigerated: 15 day(s)
Frozen (-20 ºC): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxyphenbutazone</td>
<td>mcg/mL</td>
<td>Plasma concentrations following 400 mg daily administration of oxyphenbutazone: 27 - 95 mcg/mL.</td>
</tr>
<tr>
<td>Phenylbutazone</td>
<td>mcg/mL</td>
<td>Steady-state plasma concentrations for patients administered 800 mg daily oral phenylbutazone averaged 100 mcg/mL and ranged from 60 to 150 mcg/mL. Deaths due to blood dyscrasias have been reported following therapeutic administration.</td>
</tr>
</tbody>
</table>

52103TI Phenylbutazone and Metabolite Confirmation, Tissue

Summary of Changes: Scope of Analysis was changed.
Order of Reporting was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]
Scope of Analysis: LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone

52103U Phenylbutazone and Metabolite Confirmation, Urine

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]
Test Changes

Specimen Requirements: 1 mL Urine
Transport Temperature: Frozen
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature. Received Refrigerated.
Stability: Room Temperature: Not Stable
Refrigerated: 1 day(s)
Frozen (-20 °C): 2 day(s)
Scope of Analysis: LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone

3700B Phenylbutazone and Metabolite, Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements: 2 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 15 day(s)
Frozen (-20 °C): 15 day(s)
Scope of Analysis: LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxyphenbutazone</td>
<td>mcg/mL</td>
<td>Plasma concentrations following 400 mg daily administration of oxyphenbutazone: 27 - 95 mcg/mL. The blood to plasma ratio is unknown for this compound.</td>
</tr>
</tbody>
</table>
Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenylbutazone</td>
<td>mcg/mL</td>
<td>Steady-state plasma concentrations for patients administered 800 mg daily oral phenylbutazone averaged 100 mcg/mL and ranged from 60 to 150 mcg/mL. The blood to plasma ratio is approximately 0.5. Deaths due to blood dyscrasias have been reported following therapeutic administration.</td>
</tr>
</tbody>
</table>

3700SP Phenylbutazone and Metabolite, Serum/Plasma

Summary of Changes:
- Specimen Requirements (Special Handling) were changed.
- Specimen Requirements (Rejection Criteria) were changed.
- Stability was changed.
- Scope of Analysis was changed.
- Order of Reporting was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80329)]

<table>
<thead>
<tr>
<th>Specimen Requirements:</th>
<th>1 mL Serum or Plasma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transport Temperature:</td>
<td>Refrigerated</td>
</tr>
<tr>
<td>Specimen Container:</td>
<td>Plastic container (preservative-free)</td>
</tr>
<tr>
<td>Light Protection:</td>
<td>Not Required</td>
</tr>
<tr>
<td>Special Handling:</td>
<td>Serum: Collect sample in Red top tube</td>
</tr>
<tr>
<td></td>
<td>Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.</td>
</tr>
<tr>
<td></td>
<td>Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.</td>
</tr>
<tr>
<td>Rejection Criteria:</td>
<td>Received Room Temperature. Polymer gel separation tube (SST or PST).</td>
</tr>
<tr>
<td>Stability:</td>
<td>Room Temperature: 2 day(s)</td>
</tr>
<tr>
<td></td>
<td>Refrigerated: 15 day(s)</td>
</tr>
<tr>
<td></td>
<td>Frozen (-20 °C): 15 day(s)</td>
</tr>
<tr>
<td>Scope of Analysis:</td>
<td>LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone</td>
</tr>
<tr>
<td>Method (CPT Code):</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxyphenbutazone</td>
<td>mcg/mL</td>
<td>Plasma concentrations following 400 mg daily administration of oxyphenbutazone: 27 - 95 mcg/mL.</td>
</tr>
<tr>
<td>Phenylbutazone</td>
<td>mcg/mL</td>
<td>Steady-state plasma concentrations for patients administered 800 mg daily oral phenylbutazone averaged 100 mcg/mL and ranged from 60 to 150 mcg/mL. Deaths due to blood dyscrasias have been reported following therapeutic administration.</td>
</tr>
</tbody>
</table>

3700U Phenylbutazone and Metabolite, Urine
Test Changes

Summary of Changes:
Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements:
- Transport Temperature: Frozen
- Specimen Container: Plastic container (preservative-free)
- Light Protection: Not Required
- Special Handling: None
- Rejection Criteria: Received Room Temperature. Received Refrigerated.
- Stability: Room Temperature: Not Stable
  Refrigerated: 1 day(s)
  Frozen (-20 °C): 2 day(s)

Scope of Analysis:
- Method (CPT Code): LC-MS/MS (80329): Oxyphenbutazone, Phenylbutazone

### 3781B  Piroxicam, Blood

Summary of Changes:
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements:
- Transport Temperature: Refrigerated
- Specimen Container: Lavender top tube (EDTA)
- Light Protection: Not Required
- Special Handling: None
- Rejection Criteria: None
- Stability: Room Temperature: 15 day(s)
  Refrigerated: 15 day(s)
  Frozen (-20 °C): 15 day(s)

Scope of Analysis:

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Piroxicam</td>
<td>mcg/mL</td>
<td>The usual plasma concentration during chronic 20 mg daily oral doses is 3 - 8 mcg/mL. The blood to plasma ratio is not known for this compound.</td>
</tr>
</tbody>
</table>
Test Changes

3781SP  Piroxicam, Serum/Plasma

Summary of Changes:
- Specimen Requirements (Specimen Container) were changed.
- Specimen Requirements (Light Protection) were changed.
- Specimen Requirements (Special Handling) were changed.
- Specimen Requirements (Rejection Criteria) were changed.
- Stability was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements:
- 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial
using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability:
- Room Temperature: 15 day(s)
- Refrigerated: 15 day(s)
- Frozen (−20 °C): 15 day(s)
Scope of Analysis:
- Method (CPT Code) LC-MS/MS (80329): Piroxicam

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Piroxicam</td>
<td>mcg/mL</td>
<td>The usual plasma concentration during chronic 20 mg daily oral doses is 3 - 8 mcg/mL.</td>
</tr>
</tbody>
</table>

3781U  Piroxicam, Urine

Summary of Changes:
- Specimen Requirements (Specimen Container) were changed.
- Specimen Requirements (Light Protection) were changed.
- Specimen Requirements (Rejection Criteria) were changed.
- Stability was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80329)]

Specimen Requirements:
- 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability:
- Room Temperature: 15 day(s)
- Refrigerated: 15 day(s)
- Frozen (−20 °C): 15 day(s)
Test Changes

Scope of Analysis: LC-MS/MS (80329): Piroxicam
Method (CPT Code)

4505B  Tolmetin, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]

<table>
<thead>
<tr>
<th>Specimen Requirements:</th>
<th>1 mL Blood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transport Temperature:</td>
<td>Refrigerated</td>
</tr>
<tr>
<td>Specimen Container:</td>
<td>Lavender top tube (EDTA)</td>
</tr>
<tr>
<td>Light Protection:</td>
<td>Not Required</td>
</tr>
<tr>
<td>Special Handling:</td>
<td>None</td>
</tr>
<tr>
<td>Rejection Criteria:</td>
<td>None</td>
</tr>
<tr>
<td>Stability:</td>
<td>Room Temperature: 15 day(s)</td>
</tr>
<tr>
<td></td>
<td>Refrigerated: 15 day(s)</td>
</tr>
<tr>
<td></td>
<td>Frozen (-20 °C): 15 day(s)</td>
</tr>
</tbody>
</table>

Scope of Analysis: LC-MS/MS (80329): Tolmetin
Method (CPT Code)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tolmetin</td>
<td>mcg/mL</td>
<td>Reported steady-state plasma concentrations following a 400 mg dose four times a day averaged 45 mcg/mL (range, 8 - 79 mcg/mL). The blood to plasma ratio is approximately 0.5.</td>
</tr>
</tbody>
</table>

4505SP  Tolmetin, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Light Protection) were changed.
Specimen Requirements (Special Handling) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80329)]
## Test Changes

**Specimen Requirements:** 1 mL Serum or Plasma  
**Transport Temperature:** Refrigerated  
**Specimen Container:** Plastic container (preservative-free)  
**Light Protection:** Not Required  
**Special Handling:** Serum: Collect sample in Red top tube  
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.  
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.  
**Rejection Criteria:** Polymer gel separation tube (SST or PST).  
**Stability:** Room Temperature: 15 day(s)  
Refrigerated: 15 day(s)  
Frozen (-20 °C): 15 day(s)  
**Scope of Analysis:** LC-MS/MS (80329): Tolmetin  

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tolmetin</td>
<td>mcg/mL</td>
<td>Reported steady-state plasma concentrations following a 400 mg dose four times a day averaged 45 mcg/mL (range, 8 - 79 mcg/mL).</td>
</tr>
</tbody>
</table>
## Discontinued Tests

<table>
<thead>
<tr>
<th>Test Code</th>
<th>Test Name</th>
<th>Alternative Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>3124B</td>
<td>1-Naphthol, Blood</td>
<td>3124SP - 1-Naphthol, Serum/Plasma</td>
</tr>
<tr>
<td>3124U</td>
<td>1-Naphthol, Urine</td>
<td>3124SP - 1-Naphthol, Serum/Plasma</td>
</tr>
<tr>
<td>0980U</td>
<td>Carbaryl and Metabolite, Urine</td>
<td>3124SP - 1-Naphthol, Serum/Plasma</td>
</tr>
<tr>
<td>1569U</td>
<td>Diclofenac, Urine</td>
<td>1569SP - Diclofenac, Serum/Plasma</td>
</tr>
<tr>
<td>2067U</td>
<td>Etodolac, Urine</td>
<td>2067SP - Etodolac, Serum/Plasma</td>
</tr>
<tr>
<td>2095U</td>
<td>Flurbiprofen, Urine</td>
<td>2095SP - Flurbiprofen, Serum/Plasma</td>
</tr>
<tr>
<td>2482U</td>
<td>Ketorolac, Urine</td>
<td>2482SP - Ketorolac, Serum/Plasma</td>
</tr>
<tr>
<td>3122B</td>
<td>Naphthalene and Metabolite, Blood</td>
<td>3122SP - Naphthalene and Metabolite, Serum/Plasma</td>
</tr>
<tr>
<td>3223B</td>
<td>Nonsteroidal Anti-Inflammatory Drug Panel, Blood</td>
<td>3223SP - Nonsteroidal Anti-Inflammatory Drug Panel, Serum/Plasma</td>
</tr>
<tr>
<td>3223U</td>
<td>Nonsteroidal Anti-Inflammatory Drug Panel, Urine</td>
<td>3223SP - Nonsteroidal Anti-Inflammatory Drug Panel, Serum/Plasma</td>
</tr>
</tbody>
</table>